Use of MenAfriVac™ (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns: guidance for immunization programme decision-makers and managers

Author: World Health Organization
Tags: CTC , MenAfriVac , WHO


The need to keep vaccines in a 2°C to 8°C cold chain is a constraining factor for many immunization campaigns due to limited storage capacity and/or limited ice pack freezing capacity; supplementary immunization activities planned across sub-Saharan Africa are a good example. In 2012, the license for the Serum Institute of India’s meningitis A vaccine, MenAfriVac™, was changed based on a thorough review of scientific data by regulatory authorities and the World Health Organization (WHO) to allow for the use of the vaccine for a period of up to four days at temperatures of up to 40°C in a controlled temperature chain (CTC). This document provides countries with guidance on when and how to take advantage of this flexibility.


Type Document
Language English
Country Not Specified
Publisher World Health Organization
Disease Meningcoccal meningtitis
Added by Dan Brigden
Added on 13 August 2015 13:14:26
Hits: 839
Rating Summary:
0 based on 0 votes
Add to Favourites